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1. Introduction 
There is limited detailed information regarding morbidity and toxicity following radiation 
treatment in gastric cancer. The curative effectivity of external radiotherapy necessitates 
exposure of normal tissues with significant radiation doses, and hence must be associated 
with an accepted rate of side effects. Based on the time of first treatment, complications can 
range from the acute side effects of external beam radiation therapy which resolve shortly 
after treatment to those that develop 6 months to 2 years after completion radiotherapy. 
2. An outline of anatomy and normal histology of the stomach  
2.1 Anatomy 
Anatomically stomach is divided into 4 regions: the cardiac region is surrounded by 
esophageal sphincter. The fundus lies against the diaphragm.Body (corpus) ensue from 
fundus and pylorus (pyloric antrum): ends at the pyloric sphincter which is a thickening of 
the muscle walls. (figure 1 et 2) 
2.2 Types of cells present in the stomach 
Mucous secreting cells (goblet cells) line the luminal surface of the stomach and gastric pits 
and gastric glands which produce  mucus and bicarbonate. Mucous neck cells are present in 
the neck of the gland andproduce mucin. Parietal cells (oxyntic cells) are distributed 
throughout the length of the gland, but numerous in the middle portion. Large, rounded 
cells with eosinophilic cytoplasm and centrally located nucleus. Chief cells (peptic or 
zymogenic cells) produce gastric acid. They are clustered at the base of the gland and 
identified by basally located nuclei and strongly basophilic granular cytoplasm. They 
produce pepsinogen, which digests protein. 
2.3 Normal histological features 
The gastric mucosa consists of surface epithelium, gastric pits and gastric glands. The gastric 
glands extend from the muscular mucosae to extend into the stomach lumen via gastric 
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pits.The foveolar cells lining the surface and gastric pits are identical throughout the 
stomach. Glands  differ in different regions of the stomach. Gastric pits occupy 
approximately 25% of the mucosa. Pits lie parallel to one another. These are separated by the 
lamina propria. There is more lamina propria separating the pits than between the glands. 
In normal gastric biopsy, degree of  pit and glandular separation should be same 
throughout the biopsy. Cardia is a small area of predominantly mucus secreting glands 
surrounding the entrance of the esophagus. Glands are less coiled than in the 
antralglands.The pits are shorter than the antropyloric pits.Fundus and  body are a major 
histological region consisting of straight, tubular glands. Strands of muscularis mucosae 
extend between the glands from the base. The glands secrete gastric juices as well as 
protective mucus. In pylorusbranched glands open into deep irregular shaped pits and are 
composed of mucus secreting cells. Mucus secreted by pyloric glands lubricate and protect 
entrance to the duodenum.Scattered 'G' cells (endocrine cells), secrete gastrin. Gastric 
mucosa forms a barrier todiffusion of gastric acid from the gastric lumen.The fundus is best 
seen by inverting the gastroscope to see the dome-shaped upper portion of the 
stomach.When the patient is lying on the left side, the gastric juice is seen to the left in the 
fundus, called "the mucous lake". 
 
Fig. 1. The anatomy of the human stomach  
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Fig. 2. Histology of the stomach. a three-dimensional view of layers of the stomach  
3. Critical normal tissue  
 Early reactions per definition occur within 90 days after onset of the radiation exposure. 
They are based on impairment of cell production in turnover tissues, which in face of 
ongoing cell loss results in hypoplasia and eventually a complete loss of functional cells. The 
latent time is largely independent of dose and is defined by tissue biology (turn-over time). 
Usually, complete healing of early reactions is observed. Late radiation effects can occur 
after symptom-free latent times of months to many years, with an inverse dependance of 
latency on dose. Late normal tissue changes are progressive and usually irreversible. They 
are based on a complex interaction of damage to various cell populations (organ 
parenchyma, connective tissue, capillaries), with a contribution from macrophages. Late 
effects are sensitive for a reduction in dose rate (recovery effects). A number of biologically 
based strategies for protection of normal tissues or for amelioration of radiation effects was 
and still is tested in experimental systems, yet, only a small fraction of these approaches has 
so far been introduced into clinical studies. Published data suggest that the risk of 
moderately severe (>or=Grade 3) radiation-induced acute small-bowel, pulmonary or others 
organs toxicity can be predicted with a threshold model whereby for a given dose level, D, if 
the volume receiving that dose or greater (VD) exceeds a threshold quantity, the risk of 
toxicity escalates.  One advantage of most of the methods is that they may be effective even 
if the treatment starts way after the end of radiation exposure. For a clinical exploitation, 
availability of early indicators for the progression of subclinical damage in the individual 
patient would be desirable. Moreover, there is need to further investigate the molecular 
pathogenesis of normal tissue effects in more detail, in order to optimise biology based 
preventive strategies, as well as to identify the precise mechanisms of already tested 
approaches (e.g. stem cells). 
www.intechopen.com
 
Modern Practices in Radiation Therapy 
 
252 
3.1 Radiation tolerance (radiation gastritis) 
Any discussion about the use of radiation therapy in the treatment of any cancer with 
critical normal tissue than stomach must prefaced by a description of the radiotolerance of 
stomach. It is commonly held that there is a low risk of gastritis or ulcer if the whole 
stomach receives less than 45Gy with a classic fractionation (1.8Gy or 2 Gy once a day 5 
times per week).In the rat after irradiation with single doses, three distinct gastric disorders 
were observed which occurred at different latency times. Acute death 2–3 weeks after 
irradiation was caused by ulcerative gastritis and occurred in all animals given 28.5 Gy 
without diet, in 17% of the animals given 28.5 Gy plus diet, and in 13% of the animals given 
23 Gy. Subacute to chronic fatal disorders 4 weeks to 7 months after irradiation were seen as 
stomach dilatation and gastroparesis, associated with the replacement of the normal gastric 
mucosa by a hyperkeratinized multilayered squamous epithelium(Breiter et al1989). These 
disorders occurred in 40–100% of the animals after doses between 16 Gy and 28.5 Gy (+diet). 
Late gastric obstruction exceeding 7 months after irradiation was seen in the rats because of 
profound changes in the gastric wall in 13–18% of the animals after doses between 23 Gy 
and 14 Gy. In animals surviving these three periods, an atrophic mucosa and intestinal 
metaplasia developed. From functional and morphohistological studies, it can be concluded 
that there are differences in the pathogenesis of the fatal radiation damage for each of these 
periods after irradiation. The most sensitive cells in fundus would be the parietal cells and 
chief cells. They are the first two to necrose. Glands are colonized by mucous neck cells and 
are an inflamatorylymphocitic reaction seat.  Mucous gland metaplasia, the reversible 
replacement of differentiated cells, occurs in the setting of severe damage of the gastric 
glands, which then waste away (atrophic gastritis) and are progressively replaced by 
mucous glands.Acute gastric ulcers may develop and are rather linked to a mucosa 
desquamation. Vascular necrosis occurs second time and is responsible for late 
perforation(golgraber et al 1975, roswit,et al 1972)) 
Gastric acid is produced by cells lining the stomach, which are coupled to radiotherapy, 
radiation ionizing decrease earlier acid production but only with low dose radiotherapy. 
Stemcells of the gastric mucosa seems to be insensitive to radiotherapy. In one hour ,they 
repair 60% of ADN lesions and the  stems cells doubling time is fast (about 43hours) (chen et 
al 1972). However, these in vitro data are not always correlated with clinical data on late 
effects of stomach radiotherapy. Clinically nauseas occur in the first hours after irradiation. 
Vomiting and anorexia are reported in clinical trial MALT lymphoma, lomboaortic 
radiotherapy or in preoperative gastric radiation (ajani et al 2004). Moderate (2–3 Gy of 
radiation) exposure is associated with nausea and vomiting beginning within 12–24 hours 
after exposure. 
3.2 Acute and chronic side effects 
3.2.1 Ulcer and gastritis 
The late effects of radiation gastric therapy can include ulcer and gastritis (bush 1993, otsuka 
2008). Ulcer is usually alone and in pyloric antrum. Microscopic appearance is telangectasia, 
fibrin deposit and numerous fibroblasts. Microscopic chronic gastritis appears with lympocytic 
cells mass,gastric gland are infrequent, not typical architecture, perivascular lymphocytic cells 
cluster, submucosal fibrosis dividing muscularis fibers, Intestinal metaplasia typically begins 
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in response to chronic mucosal injury in the stomach and may extend to the body. Gastric 
mucosa cells change to look like intestinal mucosa. (coia et al 1995). 
Grigsby  reported a series of 30 patients received 48Gy(1.2 Gy twice a day). One patient 
declared a toxicity grade 3. In a similar review of the literature of patients treated with 26Gy 
and a lomboaortic field (normal fractionation) in seminoma stage I, any patient presented 
late gastro intestinal toxicity (Grisgby et al 2001).  
3.2.2 Previous gastric radiation and incidence of gastric cancer 
In previous radiation therapy for benign gastric disease there are limited data to suggest 
that radiation delivered may be a risk factor for gastric cancer. Gastric radiation was used in 
the ulcer gastro-duodenal treatment. Doses ranging from 15Gy to 20 Gy in 10 fractions were 
used before prescribing the inhibitors of pump proton. In small series of patients Peters et al 
described patients with partial gastrectomy and radiotherapy had an increased  incidence of 
gastric cancer.  Grien and coll reported 1831 patients with ulcers disease who were treated 
with radiation therapy and compared them to a similar group of medically managed patient 
over an average of 22 years. Radiotherapy was linked to an increased relative risk for 
cancers of the stomach (rr=2.77 and 95% as was partial gastrectomy(rr=2.6). So if surgery 
was combined with radiation therapy the risk increased 10 fold (Griem et al 1994).  
3.3 Gastric tolerance dose 
3.3.1 Conventional fractionation 
The most of clinical information come from trials about hodgkin lymphoma, MALT (mucosa 
associated lymphoid tissue) or postoperative radiation of the paraaortic and ipsilateral 
pelvic lymph nods in testiculars tumors, or uterine cervix carcinoma. Two trials are relevant 
and expose acute and late toxicity in radiation gastric adenocarcinoma treatment. Forty 
three patients received concurrent radiation 45Gy(1.8Gy/fraction) and chemotherapy 
(infusional fluorouracil and weekly paclitaxel). Resection was attempted 5 to 6 weeks after 
chemoradiotherapy was completed. Any ulcer but gastritis grade 3 in one patient were 
noticed (ajani et al 2004). Cosset et al reported the toxicity results of 2 trials and 516 patients 
were entered in two consecutive EORTC trials for supra-diaphragmatic  Hodgkin's 
lymphoma received an sub-diaphragmatic irradiation and, 36 (7%) developed late radiation 
injuries of the gastrointestinal tract. Twenty-five patients presented with ulcers (stomach or 
duodenum), two with severe gastritis. Although there was a significant improvement of 
complication in previous laparotomy the complication rate was 2.7% without any previous 
abdominal surgery, it was 11.5% after laparotomy (p < 0.001). Fractionation was also found 
to be of importance in the occurrence of complications: three different weekly schedules 
were used -5 x 2 Gy, 4 x 2.5 Gy and 3 x 3.3 Gy; the GIT complication rates were 4, 9 and 22%, 
respectively (p less than 0.001). When combining laparotomy and fractionation, we found 
that the patients who were treated using 5 weekly fractions of 2 Gy without any prior 
laparotomy had a very low rate of late digestive complications (1%), whereas the patients 
who received 3 weekly fractions of 3.3 Gy after laparotomy presented a 39% complication 
rate. The other subgroups of patients were at an intermediate risk (from 5 to 13%) of late 
digestive injuries. The median time occurring gastric ulcer was 18 months(3-92 months). 
Authors illustrate the effect of the difference with linear quadratic equation often used to 
model biological response to radiation. For the acute effect if the ratio ǂ/ǃ =10, 40Gy(2 Gy 
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per fraction) is an equivalent to 41.7 Gy(2.5Gy per fraction) and 44.3Gy(3.3Gyper fraction). 
So a ratio  ǂ/ǃ =2.5 40Gy(2 Gy per fraction) is an equivalent to 44.4 Gy(2.5Gy per fraction) 
and 51.8Gy (3.3Gy per fraction)(Cosset al 1988). Mohiuddin studied 81 patients with 
localized, unresectable carcinoma of the pancreas with a combination of intraoperative 
Iodine-125 implantation, external beam radiation 50-55Gy with standard fractionation, and 
peri-operative systemic chemotherapy and 22% of the patients developed gastric bleeding 
mainly antral bleeding(mohiuddin et al 1992). Grisby   reported a series of 30 patients 
received 48Gy(1.2 Gy twice a day). one patient declared a toxicity grade 3(Grigsby et al 
2001). In a similar review of the literature of patients treated with 26Gy and a lomboaortic 
field (normal fractionation) in seminoma stage I, any patient presented late gastro intestinal 
toxicity(classen et al 2004).Yang et al reported radiation toxicity in 153 Patients treated for an 
hepatocarcinoma. The median dose received was 38Gy into15 fractions and a median dose 
of 3Gy. Twenty percent of the patients received an oesogastric endoscopy. Six percent of the 
patients presented gastro-duodenal ulcer and 5% gastritis. Fifty percent of the gastric ulcer 
and 75% of duodenal ulcer were in the irradiated target volume. Gastric bleeding was 
significantly commonly for femal, but not in cirhosis, total dose, dose per fraction and this 
study doesn’t identify an high risk group(yang et al 2005). In the paraaortic lymph node 
treatment, 121 patients received 50Gy normal dose per fraction, 5% presented gastro 
duodenal ulcer and 2 patients gastrectomy (Goldstein et al 1975). 
3.3.2 Hypofractionation of radiation  
In general, rates of gastric-specific toxicity are inconsistently reported in the literature, often 
in combination with other GI toxicities. Additionally, other side effects such as anorexia, 
nausea, and vomiting are often included in gastrointestinal toxicity profiles. Other authors 
have also reported GI toxicity with hypofractionated regimens. Hoyer, et al conducted, 
Phase-II study on stereotactic radiotherapyof locally advanced pancreatic carcinoma, 
conducted a Phase II trial in which 22 patients with locally advanced pancreatic 
adenocarcinoma received 45 Gy split into three fractions. These investigators reported 
significantly greater acute GI toxicity than in our previous pancreatic cancer SBRT studies. 
The greater toxicity observed in the Hoyer study may be attributed in part to the 
significantly larger treatment volumes reported in this cohort of patients. Five patients (23%) 
experienced severe mucositis of the stomach or duodenum, including one who developed a 
gastric perforation. In each of these patients, part of the stomach or duodenum received at 
least 67% of the prescribed dose (30Gy over three fractions)(Hoyer et al 2005).Guidelines 
and different trials phase I- II propose to respect Dose volume histograms (DVHs) and to 
analyze V0.5 (volume of gastric in cm3 receiving 30 Gy),  and the maximum dose to 0.5cm3 
of stomach (Dmax ≤30Gy)(Murphy et al 2009, lee et al 2009) 
Streitparth reported gastric mucosa acute tolerance to high dose rate brachytherapy. Study 
treated 33 patients and liver segment tumor II and III(near stomach). In all patients a 
minimum dose applied to 1 ml of the gastric wall (D1 ml) ranged from 6.3 to 34.2 Gy; median, 
14.3 Gy. Toxicity was present in 18 patients (55%). Nausea was present in 16 patients (69%), 
emesis in 9 (27%), cramping in 13 (39%), weight loss in 12 (36%), gastritis in 4 (12%), and 
ulceration in 5 patients (15%). they found a threshold dose D1 ml of 11 Gy for general gastric 
toxicity and 15.5 Gy for gastric ulceration verified by an univariate analysis (p = 
0.01).Authors conclude for a single fraction, small volume irradiation we found in the upper 
abdomen a threshold dose D1 ml of 15.5 Gy for the clinical endpoint ulceration of the gastric 
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mucosa the tolerance dose of gastric mucosa after EBT applied as a single fraction dose can 
be estimated at 15.7 Gy, converted by using the linear-quadratic model with an assumed 
ǂ/ǃ of 12 Gy for gastric tissue  for a TD50/5 of 70 Gy (probability of 50% during the next 5 
years after irradiation to one third of the total gastric volume) (Streitparth  et al 2006)  these 
data are in adequacy with Emami  who assessed  perforation gastric risk for 60Gy and one 
third volume of gastric treated, 5% rate severe complication at 5 years was 60Gy.(Emami et 
al 1991.) 
3.4 Guidelines to minimizing toxicity  
There are several means to reduce normal tissue toxicity when combining radiotherapy and 
chemotherapy. Generally radiotherapy fields should cover clinically evident disease only 
and not attempt to cover areas where subclinical carcinoma is likely to present.  But in 
gastric cancer and postoperative radiation or in trial with perioperative radiotherapy fields 
and clinical target volume cover all stomach organ. In the current state of the medical 
knowledge, there remains an uncertainty about dose and stomach tolerance and especially 
the ratio dose/volume and dose/time. Scientific Studies evaluating the dose and critical 
stomach organ tolerance are difficult to compare. It seems not necessary to delineate 
stomach and   it is  important to verify any hot point more than 35Gy. The ICRU “hot spot” 
(i.e. the dose outside of the PTV with a volume of at least 1.8 cc) should not exceed the 
prescription dose by more than 7%.(matzinger et al 2009) 
Thirty five Gy is probably the threshold beyond the ulcer risk increase. Fifty four Gy 
maximal dose may be administred in a small volume with a classical fractionation.In SBRT 
Guidelines propose to respect Dose volume histograms (DVHs) and to analyze V0.5 
(volume of gastric in cm3 receiving 30 Gy), and the maximum dose to 0.5cm3 of stomach 
(Dmax ≤ 30Gy)(Murphy et al 2009). 
4. Conclusion 
Stomach is a critical normal tissue that need to be considered in the radiation treatment but 
toxicities are rare and it seems not necessary to delineate stomach. But in the current state of 
knowledge there is still uncertainty about the stomach dose tolerance and especially the 
ratio dose volume and dose time. Acute toxicities, vomiting, nausea occur precociously. 
Stomach tolerance dose if the totality is irradiated is 45Gy and classical fractionation35Gy is 
the threshold beyond which the ulcer risk appear and it is possible to prescribe 54 Gy in a 
reduce volume. 
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